Sponsor:
Regeneron Pharmaceuticals
Code:
NCT07863024
Conditions
Advanced Solid Tumors
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
REGN13089-M404-M2980
Brief summary:
Conditions
Advanced Solid Tumors
Study ID
NCT07863024
Start date
Oct 28, 2026
Status verified date
Nov, 2026
Completion date
Mar 10, 2031
Anticipated
Primary completion date
Mar 10, 2031
Anticipated
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Enrollment
320 participants
Anticipated
Allocation
Randomized
Intervention Model
Sequential
Primary purpose
Treatment
Arms
experimental: Part 1: Dose Escalation
experimental: Part 2: Dose Expansion
Interventions
REGN13089-M404-M2980
Primary outcome measure
Central contacts
Locations
Carolina BioOncology Institute
Recruiting
Huntersville, North Carolina, United States, 28078
Sponsor
Regeneron Pharmaceuticals
Last update posted
Nov 18, 2026
Last verified
Nov, 2026
Keywords
Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-19. This information was provided to ClinicalTrials.gov by Regeneron Pharmaceuticals on 2026-11-18. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.